Diagnostic devices

Tender description

HealthTrust Europe (HTE) is seeking to establish a framework agreement for Point of Care Testing (POCT). It is envisaged that the framework will provide a comprehensive range of products, to include POCT equipment, associated consumables, maintenance, IT, service delivery and any other products/services that can be properly described as Point of Care Testing. The framework agreement will be split into the following Lots: Lot 1 — Blood Glucose and Ketones Testing Lot 2 — Blood Gas Analysis Lot 3 — Rapid Diagnostic Test Kits Lot 4 — Drugs of Abuse Testing Lot 5 — Urinalysis Lot 6 — Coagulation Testing Lot 7 — HbA1c Testing Lot 8 — Cholesterol Testing Lot 9 — Cardiac Markers Lot 10 — Multi Test Systems Lot 11 — Single Test Systems Lot 12 — Interfacing and Connectivity Lot 13 — Mini Competition / GPO Committed Spend Please see section VI.3 for further information regarding supplier engagement and expression of interest. It is anticipated that the scope of Lot 1 (Blood Glucose and Ketone Testing) will include a range of POCT blood glucose testing meters/instruments and any associated consumables which would allow Blood Glucose analysis to be completed using a blood sample from a patient, in settings, such as acute and primary care settings. Ketone testing is an optional test which may be provided for under this Lot. It is anticipated that the scope of Lot 2 (Blood Gas Analysis) will include a range of POCT blood gas and electrolyte analysers, suitable for Point of Care testing, as well as (but will not be restricted to) any associated consumables, reagents and IT software, able to deliver rapid and reliable results. It is anticipated that Lot 3 (Rapid Diagnostic Test Kits) will include a range of test kits which can be used to provide rapid results of a number of tests at the point of patient care. These tests may include, but will not be limited to, pregnancy test kits, HIV test kits, malaria test kits, Strep A test kits, Influenza test kits and Urease (H.pylori) test kits. It is anticipated that Lot 4 (Drugs of Abuse) will include a range of products which enable the identification of drugs or alcohol in a urine sample, or any other associated samples, producing real time results. It is anticipated that Lot 5 (Urinalysis) will include POCT analysers and any associated consumables which will allow monitoring of changes of a range of parameters in a patient's urine. It is anticipated that Lot 6 (Coagulation Testing) will include POCT analysers and any associated consumables which will measure the affect of anti-coagulation through blood analysis. It is anticipated that Lot 7 (HbA1c (Glycated haemoglobin)) will include POCT analysers and any associated consumables which are used to monitor the measurement of HbA1c in a patient's blood. This Lot may also include other tests which are associated with diabetes management. It is anticipated that Lot 8 (Cholesterol Testing) will include POCT analysers and any associated consumables which are used to assess the risk of developing heart disease in a patient, via blood analysis. It is anticipated that Lot 9 (Cardiac Markers) will include POCT analysers and any associated consumables which will identify various cardiac markers, allowing diagnosis of acute coronary symptoms via analysis of the patient's blood. It is anticipated that Lot 10 (Multi Test Systems) will include POCT analysers and any associated consumables, reagents or IT software which can produce real-time results from a range of testing areas. It is anticipated that Lot 10 (Single Test Systems) will include POCT analysers/meter which is able to analyse the sample for one parameter only with a low throughput. It is anticipated that Lot 12 (Interfacing and Connectivity) will include IT software to allow Participating Authorities to connect POCT systems running within primary and secondary care and extending outside into the wider community. Lot 13 (Mini Competition / Committed GPO) will allow Participating Authorities to both run a mini competition for an individual authority, as well as aggregate spend between a number of Authorities in line with Health Trust Europe's GPO model. For further information about the Health Trust Europe GPO model, please refer to www.healthtrusteurope.com/group-purchasing